Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period - Deitcher, SR; Kessler, CM; Merli, G; for the ONCENOX Investigators (Clin Appl Thromb Haemost, 2006)